Coenzyme Q10 is a fat-soluble helper molecule the body makes for cellular energy. Production falls with age and cholesterol-lowering drugs. Evidence is strongest in heart failure, with further support for blood pressure, migraine, fatigue, blood fats, fertility-treatment pregnancy, and mood. Parkinson motor decline was not slowed. Lifespan extension from CoQ10 alone is unproven. Stomach upset is the usual side effect. (Full Review)
| Marker | Target | Why |
|---|---|---|
| Plasma CoQ10 | ≥2.0 µg/mL on therapy | Confirms absorption and a supplemented steady state |
| Seated systolic/diastolic blood pressure | <120/80 mmHg functional | Tracks the most replicated cardiometabolic surrogate |
| LDL-C | Individual target (often <70–100 mg/dL in high-risk prevention) | Small CoQ10 lipid shifts are not statin-scale change |
| HbA1c (if diabetic or prediabetic) | Individual target (often <5.7% metabolic; <6.5% diagnostic) | Tracks glucose status; CoQ10's glycemic effect is not established |
| CK (if on a statin) | Stay within the lab reference interval or the person's own baseline | Separates subjective myalgia from enzyme-defined injury |
| INR (if on warfarin) | Stay in the person's prescribed therapeutic band | Catches a possible CoQ10–warfarin shift |
Cadence: Baseline before the first dose; 8–12 weeks; then every 6–12 months. INR recheck 3–7 days after starting or stopping if on warfarin